Technical Analysis for TERN - Terns Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Reached Oversold | Weakness | 0.00% | |
| BB Squeeze Ended | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | -2.08% | |
| BB Squeeze + Lower Band Touch | Range Contraction | -2.08% | |
| Below Lower BB | Weakness | -2.08% | |
| Lower Bollinger Band Touch | Weakness | -2.08% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Possible NR7 | about 9 hours ago |
| 60 Minute Opening Range Breakdown | about 13 hours ago |
| Gap Up Closed | about 13 hours ago |
| Gap Up Partially Closed | about 13 hours ago |
| Down 3% | about 13 hours ago |
Get a Trading Assistant
- Earnings date: 11/07/2023
Terns Pharmaceuticals, Inc. Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase 2a clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase 1 clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Foster City, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Steatohepatitis Hepatitis Non Alcoholic Fatty Liver Disease Peptide Hormones Liver Bile Acid Chronic Liver Diseases Glucagon Anti Diabetic Drugs
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 14.0435 |
| 52 Week Low | 4.38 |
| Average Volume | 602,565 |
| 200-Day Moving Average | 9.11 |
| 50-Day Moving Average | 5.93 |
| 20-Day Moving Average | 5.19 |
| 10-Day Moving Average | 5.10 |
| Average True Range | 0.33 |
| RSI (14) | 30.56 |
| ADX | 40.25 |
| +DI | 13.11 |
| -DI | 29.43 |
| Chandelier Exit (Long, 3 ATRs) | 4.65 |
| Chandelier Exit (Short, 3 ATRs) | 5.60 |
| Upper Bollinger Bands | 5.57 |
| Lower Bollinger Band | 4.81 |
| Percent B (%b) | -0.15 |
| BandWidth | 14.68 |
| MACD Line | -0.30 |
| MACD Signal Line | -0.32 |
| MACD Histogram | 0.0188 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.20 | ||||
| Resistance 3 (R3) | 5.22 | 5.07 | 5.11 | ||
| Resistance 2 (R2) | 5.07 | 4.95 | 5.06 | 5.08 | |
| Resistance 1 (R1) | 4.89 | 4.87 | 4.82 | 4.87 | 5.06 |
| Pivot Point | 4.74 | 4.74 | 4.71 | 4.73 | 4.74 |
| Support 1 (S1) | 4.56 | 4.62 | 4.49 | 4.54 | 4.34 |
| Support 2 (S2) | 4.41 | 4.54 | 4.40 | 4.32 | |
| Support 3 (S3) | 4.23 | 4.41 | 4.29 | ||
| Support 4 (S4) | 4.21 |
